[Form 3] Evogene Ltd. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Evogene Ltd. director Falk Dan Michael reported his initial holdings of stock options linked to the company’s ordinary shares. The Form 3 shows four option grants with exercise prices of $10.51, $6.03, $7.16, and $1.29 per share and expiration dates ranging from September 2032 to August 2035. These options cover 1,800, 1,800, 1,800 and 2,500 underlying ordinary shares, all held directly. A footnote explains that the 2,500-share grant vests in four equal quarterly installments of 25% each, becoming fully vested on the one-year anniversary of the August 18, 2025 grant date.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Falk Dan Michael

Role Director

Type	Security	Shares	Price	Value
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--
holding	Stock Option (right to buy ordinary shares)	--	--	--

Holdings After Transaction: Stock Option (right to buy ordinary shares) — 1,800 shares (Direct)

Footnotes (1)

1. [object Object]

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Falk Dan Michael

(Last) (First) (Middle)

10 HAALIYA HASHNIYA ST.

(Street)

HERZELIYA 4632012

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Evogene Ltd. [ EVGN ]

3a. Foreign Trading Symbol
[EVGN]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	09/15/2023	09/15/2032	Ordinary shares	1,800	$10.51	D
Stock Option (right to buy ordinary shares)	05/11/2024	05/11/2033	Ordinary shares	1,800	$6.03	D
Stock Option (right to buy ordinary shares)	06/13/2025	06/13/2034	Ordinary shares	1,800	$7.16	D
Stock Option (right to buy ordinary shares)	(1)	08/18/2035	Ordinary shares	2,500	$1.29	D

Explanation of Responses:

1. The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.

	/s/ Nitsan Deutsch, attorney-in-fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Evogene (EVGN) Form 3 filing report for Falk Dan Michael?

The Form 3 shows Falk Dan Michael’s initial beneficial ownership in Evogene via stock options. It lists four option grants over ordinary shares, detailing their exercise prices, expiration dates, and the number of underlying shares held directly as a company director.

How many Evogene ordinary shares are covered by Falk Dan Michael’s options?

The filing records options over 1,800, 1,800, 1,800 and 2,500 Evogene ordinary shares. These four grants together represent multiple option packages, each with its own exercise price and expiration date, reflecting his derivative-based equity exposure as a director.

What are the exercise prices of Falk Dan Michael’s Evogene stock options?

The disclosed options have exercise prices of $10.51, $6.03, $7.16 and $1.29 per ordinary share. Each price applies to a specific grant with its own expiration date, defining the cost at which he can purchase Evogene shares if he chooses to exercise.

When do Falk Dan Michael’s Evogene stock options expire?

The option grants expire in stages between September 2032 and August 2035. Each block of options linked to ordinary shares has a specific expiration date, giving several multi‑year windows during which he may choose to exercise the rights if conditions are favorable.

How do the 2,500-share Evogene options granted in August 2025 vest?

According to the footnote, the 2,500-share option grant vests quarterly at 25% per quarter. The vesting schedule begins from the August 18, 2025 grant date and continues so that the options are fully vested on the one-year anniversary of that date.